- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Six independent Board members from the pharmaceutical industry and finance
BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced the reinforcement of its Supervisory Board following the latter's renewal at the April 29th General Shareholders' Meeting. The Supervisory Board of 6 members is committed to supporting the company's growth. Four members are coming from pharmaceutical or specialty pharma companies and two from the financial world.
"I wish to express my thanks to our departing Chairman Jean-Claude Deschamps for his support for BioAlliance Pharma and to all the other departing Board members. Georges Hibon, François Sarkozy and I are delighted to welcome Jean-Marie Zacharie as our new Chairman and Christophe de Backer, Gilles Marrache and Philippe Taranto as new Board members. This new team has a wealth of complementary skills and experience for performing its governance tasks and supporting the company in its growth phase", stated Dominique Costantini, President of the Management Board at BioAlliance Pharma.
The new Supervisory Board
Jean-Marie Zacharie, Chairman - 67 years of age, Chairman of MSD - Chibret France until 2006 and Vice President Europe from 2001 to 2006. He previously managed a number of Merck MSD subsidiaries around the world, in Spain and South America. Prior to that, he worked at Sandoz as CEO of the company's Belgian subsidiary and Vice-President for the Middle East and Africa. He started his career in marketing at Sandoz Japan. Jean-Marie Zacharie is a graduate of the HEC Paris School of Management (class of 1964), INSEAD (1965), Columbia University (Senior Management Program, 1980) and Stanford University (Senior Executive Program, 1990).
François Sarkozy, MD, Vice Chairman - 48 years of age, Director of the AEC Partners consulting firm, which he joined as a partner in 2001. From 1990 to 2000, he successively served as Medical Director, France, at Aventis Pharma and Medical & Pharmaceutical Director, France, at Hoechst Marion Roussel, after having been International Development Director at Roussel-Uclaf. From 1983 to 1990, he worked as an assistant house officer at the Paris Public Hospitals Group, where he performed his internship in pediatric medicine.
Dr François Sarkozy also holds an MBA from INSEAD.
Christophe de Backer - 46 years of age, Deputy CEO of HSBC France since September 2007. He started his career at Oddo at the French institutional sales desk. Following his recruitment by CCF in 1991, he was appointed as CEO and Chairman of CCF Securities in 1998 and, three years later, as Deputy CEO of CCF's private asset management arm and thus CEO and Chairman of HSBC CCF Asset Management Holdings. In 2005, he was appointed Chairman of the Executive Board of HSBC Private Bank France.
Christophe de Backer is a graduate of the ISG School of Management (class of 1986).
Georges Hibon - 70 years of age, with over 35 years of pharmaceutical industry experience, especially at Merck (where he spent 18 years in a series of executive positions in the company's European and international operations) and including 8 years with Pasteur Mérieux Connaught (now Sanofi Pasteur), which he left in 1998 after serving as Chairman and CEO of Pasteur Mérieux Connaught North America. Board member at CEREP since 2000 and at Biomérieux since 2004; Board member and Chairman of Shanta Biotechnics, Hyderabad, India since 2006 and Chairman of Advanced Bioscience Laboratories, Washington, USA.
Georges Hibon is a graduate of HEC Paris School of Management.
Gilles Marrache - 40 years of age, CEO of Amgen France and Vice-President of Amgen Inc. since January 2006 (incorporated in 1980, Amgen is a specialty pharma and the biotech industry leader). Gilles Marrache was appointed as Country Manager for Belgium and Luxembourg in 2004. He had previously (in 2002) headed up Amgen's oncology division in France. Prior to joining Amgen, he had served in a number of executive positions at Novartis Pharma France (Marketing Director, Commercial Director and Oncology Division Director), where he was involved in launching Glivec and Zometa. He started his career at the wholesaler CERP.
Gilles Marrache is a Pharm. D. and holds an MBA from ISC Paris.
Philippe Taranto - 46 years of age, Associate Director at NI Partner investment fund (Natexis Private Equity Group) since January 2006. From 1987 to 2005, he successively held the positions of Investment Director at Paribas Affaires Industrielles and of Associate Director at Paribas Affaires Industrielles Partners with responsibility for its investments in the healthcare and chemical sectors (such transactions as Unilabs, Effik, Hexagone Hospitalisations, Jouan, Ipsen Beaufour, Ceva Santé animale). He started his career as a financial analyst in the Banking Department at Paribas.
Philippe Taranto is a graduate of HEC Paris School of Management (class of 1984) and was awarded the French Society of Financial Analysts diploma in 1987.
About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and already received European Marketing Authorizations in UK, Germany, Belgium, Denmark and Luxemburg. The compound has completed the pivotal Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.
In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and in the USA with Par Pharmaceutical. In March 2008, BioAlliance Pharma signed a partnership agreement with Handok Pharmaceuticals for commercializing Loramyc® in Korea, Taiwan, Singapore and Malaysia. In May 2008, the company expanded its product portfolio via acquisition of the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD).
For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).
For more information, please click here
BioAlliance Pharma SA
President and CEO
+33 1 45 58 76 01
+33 1 45 58 71 00
+33 6 64 18 99 59
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information